Posted in | Nanobusiness

Nanogen Diagnostic Tool to Test for Schizophrenia Markers

Published on July 12, 2007 at 11:51 AM

Nanogen, Inc., developer of advanced diagnostic products, announced today that it has entered into an agreement whereby the company acquired rights to genetic markers related to schizophrenia and responses to antipsychotic therapies. The agreement is between Nanogen and the Co-operative Research Centre for Diagnostics and Queensland University of Technology in Australia.

Nanogen plans to utilize the markers to create diagnostic tests for schizophrenia and related conditions. Some of these markers may also help predict adverse drug reactions and therefore guide therapeutic decision-making.

“Schizophrenia affects approximately one percent of the U.S. population, with an estimated cost to the health care system of $63 billion annually,” said David Ludvigson, Nanogen’s president and chief operating officer. “Due to its complexity - schizophrenia, like many mental disorders, is believed to be caused by mutations in multiple genes - development of effective diagnostics and treatments is likely to require multiplexed analytic methods capable of examining multiple genes simultaneously.”

Nanogen’s NanoChip® multiplexing platform was recently submitted for FDA 510(K) clearance, along with the company’s cystic fibrosis carrier screening test.

The genetic component of schizophrenia is thought to account for 65-80% of the disease risk. The markers acquired by Nanogen are in genes that have been linked to schizophrenia in a number of clinical studies. 

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit